UroGen Pharma Ltd - URGN Net Assets per Single Share

Public company logo of UroGen Pharma Ltd (URGN)

The price action for UroGen Pharma Ltd. (URGN) is presented below; the company complies with environmental regulations through waste disposal, and the current metric stands at -2.73. The business relies on unique patents in the field of local chemotherapy and strict FDA oversight. The developed targeted therapy ecosystem utilizes proprietary gels for drug delivery, making their methods indispensable for treating complex urinary tract tumors.

UroGen Pharma Ltd (URGN) - Accounting Value per Share from 07/04/2022 to 10/28/2026

Summary analytical data breakdowns for urogen.com (URGN)

- price and consensus price forecast:
Stock Price UroGen|URGN - Analyst Target Range
- market capitalization data:
Market Value UroGen Pharma Ltd.|URGN - Business Value
- book capitalization data:
Book Value per Share UroGen Pharma|URGN - Company Net Assets|Market Capitalization to Book Value Ratio urogen.com|URGN - Company Total Assets
- debt and liquidity data:
Debt to Equity UroGen Pharma Ltd.|URGN - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital UroGen Pharma|URGN - Company Total Debt|Debts to Book Capitalization UroGen Pharma Ltd.|URGN - Long-Term Debt|Company Short-Term Debt UroGen Pharma
Analysis of all company metrics:UroGen, URGN
Manufactured product of urogen.com

Book value per share determines the portion of net assets attributable to a single security. This metric is calculated as the difference between all company assets and liabilities, divided by the number of shares. The historical assessment of book value per share demonstrates equity dynamics. For UroGen Pharma Ltd. (URGN), this is a critical marker of resilience against expansion by big pharma behemoths. A decline in this metric may signal equity dilution amid intense competition.

Competitor analysis for UroGen Pharma Ltd.

Book Value per Share ONC|HALO: Book Value of One Share|Net Assets per Single Share Revolution Medicines|ascentage.com (AAPG) - Equity per Share|Book Value per Share CGON|Accounting Value per Share Bicara Therapeutics Inc|Book Value per Share PSNL|Book Value per Share ERAS (Erasca Oncology)|DCTH - Net Assets per Single Share|Equity per Share ymabs.com YMAB|AURA: Book Value per Share|CADL - Accounting Value per Share|Book Value per Share ARAY|SLS (SELLAS Life Sciences Group) - Net Asset Value per Share|ACTU - Net Assets per Single Share|Accounting Value of a Share citiusonc.com (CTOR)|TuHURA Biosciences, Inc. (HURA) - Accounting Value per Share|Accounting Value of a Share Protara Therapeutics Inc (TARA)|Fate Therapeutics Corp - Book Value per Share|WHWK - Accounting Value per Share|TScan - Accounting Value per Share|CSBR: Book Value per Share|Net Assets per Single Share xbiotech.com XBIT|CEL-SCI (CVM) - Accounting Value of a Share|Book Value per Share OSTX (OS Therapies Inc)|Net Asset Value per Share radiopharmtheranostics.com (RADX)|Accounting Value per Share ARTV|Book Value per Share ANL (adlainortye.com)|Net Assets per Single Share Veru|Tempest Therapeutics Inc - Accounting Value of a Share|XLO (Xilio) - Net Assets per Single Share|RENB - Net Asset Value per Share|Book Value per Share MURA (muraloncology.com)|Kairos Pharma (KAPA) - Book Value of One Share|Book Value per Share OKUR (OnKure Therapeutics, Inc.)|Net Asset Value per Share GDTC|Net Assets per Single Share Curis, Inc. CRIS|Equity per Share apollomicsinc.com APLM|Accounting Value per Share Tharimmune, Inc.|Advanced Biomed Inc. - Accounting Value of a Share|Net Assets per Single Share Genprex|CLDI - Share Book Value|Book Value per Share Sunshine Biopharma, Inc. SBFM|Xenetic Biosciences, Inc. (XBIO) - Accounting Value of a Share|SLRX (Salarius Pharmaceuticals) - Book Value per Share|Book Value per Share PPBT|American Oncology Network (AONC) - Net Assets per Single Share|Accounting Value of a Share BGNE (BeiGene Ltd.)|Checkpoint Therapeutics, Inc - Net Assets per Single Share|Accounting Value per Share elevationoncology.com ELEV|iCAD Corp - Book Value per Share|Ikena Oncology, Inc. (IKNA) - Book Value per Share|Accounting Value per Share Notable Labs NTBL|VIRX (Viracta Therapeutics, Inc.) - Accounting Value of a Share|Net Assets per Single Share MorphoSys Corp|Net Assets per Single Share NAYA Biosciences Corp (NAYA)|Accounting Value per Share Ascentage Pharma Group